-
1 missing!
Time of Update: 2021-10-22
Everyone should remember that on September 30th, on the eve of National Day, the Guangdong Provincial Drug Trading Center issued the "Guangdong Union Diclofenac and other 153 drug groups with a large amount of procurement documents (draft for comments)", covering three types of drugs including blood products and basic infusions.
153 varieties are procured in quantity.
-
The domestic pharmaceutical machinery industry is ushering in a new period of development opportunities, and two major problems need to be resolved urgently
Time of Update: 2021-10-22
In addition, under the "three-child concept", the demand for children's drugs may also grow further, and the production capacity of related pharmaceutical companies is expected to usher in a new round of expansion and upgrade, and this impact may also indirectly affect the upstream pharmaceutical equipment industry.
-
Eisai China won the 2020 Economic Contribution Award-Outstanding Contribution Award for Output Efficiency
Time of Update: 2021-10-22
Suzhou, October 8, 2021/PRNewswire/ - On September 28, Eisai China won the 2020 Economic Contribution in the 2021 Suzhou Municipal Government’s exchange activities with multinational companies and the awarding ceremony of the honorary title of Suzhou’s foreigners Award-Outstanding Contribution Award for Output Benefits, in recognition of the remarkable, iconic and leading contribution to Suzhou's economic development .
-
With the continuous expansion of the market size of Chinese herbal medicine decoction pieces, ensuring high-quality development has become a top priority
Time of Update: 2021-10-22
. Industry analysis believes that, in fact, in recent years, market regulatory authorities in various regions have been constantly "strikes out", strengthened special rectification of traditional Chinese medicine decoction pieces, actively promoted standardized production, strengthened supervision of pesticide residues, and regulated the operation and use behavior of traditional Chinese medicine decoction pieces.
-
Children's drug concept stocks are booming, and many R&D and production companies report net profits increase by more than 30%
Time of Update: 2021-10-21
Poinsettia released a semi-annual performance report on the evening of July 29, stating that the operating income for the first half of 2021 was about 953 million yuan; the net profit attributable to shareholders of listed companies was about 1.
-
The exclusive varieties are missing!
Time of Update: 2021-10-21
Prior to this (September 30), the Guangdong Provincial Pharmaceutical Exchange Center issued the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)", involving 153 varieties, including 3 blood products, 4 basic infusions and There are 146 other drugs, of which 50 are exclusive varieties (after grouping, now 51), see the attached table at the end of the article .
-
Shanghai Pharmaceuticals introduced a new antacid drug P-CAB for RMB 690 million, and the competitive landscape continues to be reshaped
Time of Update: 2021-10-21
With the first dose of full effect, strong acid suppression and unaffected by meals, the global sales of P-CAB drugs have maintained a good growth momentum against the background of continuous decline in sales of PPI inhibitors .
-
Sanofi clopidogrel aspirin tablets approved in China
Time of Update: 2021-10-21
Public information shows that this is an anti-platelet single-tablet compound (SPC), which is suitable for preventing atherosclerotic thrombosis in adult patients with acute coronary syndrome who have taken clopidogrel and aspirin at the same time .
Chinese expert consensus on antiplatelet therapy of clopidogrel/aspirin single-tablet compound preparation[J].
-
The third quarterly report intensive disclosure period!
Time of Update: 2021-10-21
It is understood that there are two main factors driving the growth of Yanan Bikang’s performance: First, the new energy products of Jiujiujiu Technology, a subsidiary of Yan’an Bikang, are affected by market demand, the release of production capacity, and the increase in market prices, resulting in profit compared with last year.
-
2021 Veeva China Business and Medical Summit is about to open
Time of Update: 2021-10-21
Shanghai, October 13, 2021/PRNewswire/ - Veeva Systems (NYSE: VEEV), a global life science industry-based solution provider based on the cloud computing model, officially announced that it will be in
-
Since September, companies in the pharmaceutical industry have been heavily "buy, buy, buy" by institutions
Time of Update: 2021-10-21
4058 million yuan, and a discount rate of 5%; in September, Shengxiang Biotech’s institutional dedicated seats appeared in a total of 8 large transactions.
-
With local pharmaceutical companies investing heavily in innovation, R&D costs have soared
Time of Update: 2021-10-21
31 billion yuan, of which the R&D expenditure in the pharmaceutical manufacturing industry will reach 784.
For example, as listed biomedical companies on the Sci-tech Innovation Board continued to increase R&D investment in the first half of the year, the total R&D investment amount has reached 5.
-
The disclosure of the third quarterly report is imminent, who are the ones that are expected to be happy for the performance of the sci-tech innovation board drug companies?
Time of Update: 2021-10-21
According to incomplete statistics, as of October 11, 13 sci-tech innovation board companies have disclosed their performance forecasts for the first three quarters, of which 10 stocks are pre-happy, accounting for more than 70%, and the overall performance is relatively good .
-
With the accelerated innovation of pharmaceutical companies, the AI drug research and development track is getting hotter and hotter
Time of Update: 2021-10-21
For a long time, new drugs have been characterized by difficult design, high cost, and time-consuming. On average, the industry’s previous research and development of a new drug required "10 years an
-
After October 15, the prices of medicines in many places will be greatly reduced
Time of Update: 2021-10-21
For example, Shandong Province recently issued the "Notice on the Implementation of the Results of the Fifth Batch of National Organizations' Centralized Purchase of Drugs", requiring all public medical institutions and military medical institutions in Shandong Province to participate in voluntary participation from October 15, 2021.
-
The market for inhalation preparations is booming, and many pharmaceutical companies have completed billions of yuan in financing during the year!
Time of Update: 2021-10-21
Public information shows that Changxi Pharmaceutical is a clinical stage biomedical company for the discovery, development and industrialization of new drugs that seriously affect the quality of human daily life, including respiratory diseases, and has patent-protected dry powder preparation technology and Efficient and convenient inhaler technology .
-
12 products of China Resources Double Crane were awarded "2021 Excellent Product Brand in the Chemical and Pharmaceutical Industry"
Time of Update: 2021-10-21
At the meeting, the "2021 Chemical Pharmaceutical Industry Excellent Enterprise and Excellent Product Brand Cultivation Plan" list was released, and 12 products under China Resources Shuanghe were rated as "Excellent Product Brands" .
-
Under policy changes, chain drugstore giants are expected to undertake sustained high performance
Time of Update: 2021-10-21
In recent years, with the advancement of policies such as prescription outflows, public hospital reforms, medical insurance control fees, volume purchases, and "dual channels", the pharmaceutical retail industry has undergone tremendous changes, and the industry concentration has continued to increase.
-
CDE publicly solicits opinions on 2 technical guidelines
Time of Update: 2021-10-21
On October 11, the CDE official website publicly solicited opinions on two technical guidelines, namely, the technical guidelines for the clinical research and development of rare disease drugs and the technical guidelines for the design of long-acting granulocyte colony stimulating factors to prevent infection after chemotherapy (draft for comments) .
-
Merck's new crown oral drug Molnupiravir submits EUA to FDA
Time of Update: 2021-10-21
On October 11, Merck announced that it had submitted an emergency authorization application (EUA) for the oral antiviral drug Molnupiravir (MK-4482) to the FDA .
If approved, Molnupiravir will become the first oral antiviral drug for COVID-19 .
